Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Thoughts on the Dermal Injector

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Oct 14, 2021 5:51pm

118 Views

Post# 34007108

RE:RE:RE:Thoughts on the Dermal Injector

Yes you would think Yofoto would want to launch the Phase 2 trials in China as soon as they were ready to go and not wait for the Dermal Injector to be used. On the other hand it lends credibility to the device for marketing purposes.

As far as the name of the device from the Sept. 29th tweet:

"The electronic engineers behind the scenes of our RCI-02 dermal injector (brand name to be announced soon btw)....."
Yet another example of the overused word "soon" by Replicel.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season